Hi KMBJN - Not sure if the question was directed at me but since I have been in this thread today in response to your question, the 200mg/kg mouse dosage amounts are what Cellceutix shows on their web page when it concern tumor response in lung, breast, colon and head and neck cancers, no dosage amounts are provided for the prostate and retinoblastoma studies. The questions arose from converting the mouse doses to HED by using the Baur BSA formula which is more correctly used for determining starting points for Phase I studies as opposed to direct conversions of dosages for human efficacy. I agree with "trusting Menon's expertise" and it is very evident many factors are involved in conversions. In additions these conversions are typically used for drugs that directly impact tumors by various mechanisms, so are they valid for a drug that restores P53, which in turn impacts tumors? With all the questions this process brought up I go back to the observed effects we have seen thus far, some patients having restaging/tumor arrest and multiple cycles/cohorts for multiple patients, thus a benefit was observed to those patient. That is important, (plus increased P21 expression in lymphocytes).
To end on an upbeat note tonight I wanted to pass along some interesting info regarding brilicidin. Recently Cellceutix said "B" is stable at room temp., I am not sure if that is in liquid or powder form. My daughter is a neurosurgical nurse and they routinely use Vancomyacin both in solution (mixed with saline by the nurse) and interestingly also in powder form within open incisions/surgical sites (mostly in back/neck surgeries I believe but perhaps other types of surgeries too) prophylactically. I wonder if "B" could also be used in this manner? Perhaps one of the posters who has a good history with correspondence with Leo (WildforCTIX) could pose the question if "B" can be used in powder form, just another potential use to consider.
News 
Market Data 
Discover 
AI
